Researchers question WHO guidelines on non-sugar sweeteners, citing a reliance on biased prospective cohort studies over randomized controlled trials. The study calls for an urgent re-evaluation of WHO’s stance, as recent evidence suggests non-sugar sweeteners may actually reduce cardiometabolic risks.
Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)
Pfizer is targeting a steady 2025, promising pipeline trims, cost cuts and smaller deals as it works to reassure investors about its path forward. …
December 18, 2024